Damora Therapeutics, Inc.
NASDAQ:DMRABiotechnology
+$0.07 today
- Market cap
- $1.42B
- Beta
- 1.48
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$177.15
Volume 0.58M
Average 0.33M
DMRA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Damora Therapeutics, Inc.NASDAQ: DMRA
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $23.78M rose 3406.9% year over year, behind the +4762.0% change in trailing-twelve-month research & development. Sequentially, it fell 88.0% from the prior quarter. Over 3 fiscal years it compounded at +61.0% a year.
Context
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +3406.9% toward the trailing-twelve-month pace of +4762.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 201.19M USD
- Year-over-year change
- +3044.5%
- 4-year CAGR
- +51.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 201.19M | +3044.5% |
| FY2024 | 2024-12-31 | 6.4M | -73.1% |
| FY2023 | 2023-12-31 | 23.77M | -50.7% |
| FY2022 | 2022-12-31 | 48.21M | +25.2% |
| FY2021 | 2021-12-31 | 38.49M | — |
Research & Development vs competitors
How DMRA compares with its peers on the latest reported figures
- DMRA's LTM Mar 2026 research & development of $224.29M is the 3rd highest of the 9 companies compared; the peer median is $114.89M.
- Its year-over-year change of +4762.0% is the highest of 7, against a peer median of +2.2%.
- Over three fiscal years its annual growth of +61.0% compares with a peer median of -8.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $2.15B | +9.1% | +8.9% | 37.0% | |
| LTM Jun 2026 | $1.78B | — | -34.5% | 43.1% | |
DMRADamora Therapeutics, Inc. | LTM Mar 2026 | $224.29M | +4762.0% | +61.0% | — |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $183.14M | +22.7% | +72.2% | — |
| LTM Mar 2026 | $132.76M | -4.7% | -10.7% | 733.7% | |
| LTM Mar 2026 | $97.03M | -47.3% | +14.1% | 292.4% | |
| LTM Mar 2026 | $73.59M | -17.7% | -8.3% | 37.5% | |
COAGHemab Therapeutics Holdings, Inc. Common Stock | FY2025 | $59.63M | — | — | — |
| LTM Mar 2026 | $36.54M | +41.7% | -17.9% | 12.2% | |
| Peer median (excluding DMRA) | $114.89M | +2.2% | -8.3% | 40.3% | |
Competitors are the stored peer set for DMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 441K | 490K | 830K | 181K | 0 |
| Gross Profit | (441K) | (490K) | (830K) | (181K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 38.49M | 48.21M | 23.77M | 6.4M | 201.19M |
| Selling, General & Admin | 13.3M | 12.51M | 11.86M | 10.32M | 9.69M |
| Operating Expenses | 51.79M | 60.72M | 35.63M | 16.72M | 210.87M |
| Depreciation & Amortization | 441K | 490K | 830K | 181K | 34K |
| EBITDA | (51.31M) | (61.13M) | (37.52M) | (21.22M) | (209.76M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (52.23M) | (61.21M) | (36.46M) | (16.9M) | (210.87M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 156K | 722K | 1.69M | 844K | 1.17M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 475K | (417K) | (1.89M) | (4.5M) | 1.08M |
| Income Before Tax | (51.75M) | (61.62M) | (38.35M) | (21.4M) | (209.79M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 41K | 50K |
| Net Income | (51.75M) | (61.62M) | (38.35M) | (21.44M) | (209.84M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (51.22) | (60.63) | (36.08) | (18.53) | (158.13) |
| EPS (Diluted) | (51.22) | (60.63) | (36.08) | (18.53) | (158.13) |
| Weighted Avg Shares | 1.01M | 1.02M | 1.06M | 1.16M | 1.33M |
| Weighted Avg Shares (Diluted) | 1.01M | 1.02M | 1.06M | 1.16M | 1.33M |
Damora Therapeutics, Inc.
NASDAQ:DMRA
Intrinsic Alpha fair value
Locked
Current Price
$22.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.